Researchers identify fexinidazole as potential new therapy for visceral leishmaniasis

Published on February 3, 2012 at 3:38 AM · No Comments

Researchers at the University of Dundee have identified fexinidazole as a possible, much-needed, new treatment for the parasitic disease visceral leishmaniasis.

Leishmaniasis is named after William Leishman, a Glasgwegian doctor serving with the British Army in India, who first identified the parasite in the early 1900s. The disease is the second biggest killer in Africa, Asia and Latin America after malaria, and affects 500,000 people, killing about 50-60,000 patients per year. Current drug treatments for the disease are unsatisfactory for reasons such as high cost, drug resistance or the need for hospitalisation.

Fexinidazole is already in phase 1 clinical trials for a related disease - African sleeping sickness - but a research team at Dundee including Dr Susan Wyllie, Professor Alan Fairlamb and colleagues has identified it as having potential in treating leishmaniasis.

Their research has been published by the journal Science Translational Medicine, and was funded by the Wellcome Trust.

Tests in mice showed that the drug has a greater than 98% rate of suppressing infection of leishmaniasis, comparable to current treatments such as miltefosine and Pentostam.

These and other existing treatment options all suffer from disadvantages; they are not always safe, effective or easy to administer. The only oral drug miltefosine cannot be given to women of child-bearing age due to a substantial risk of birth defects; other drugs are costly and have to be given by injection. Thus there is a continuing need for safe and cost-effective drugs suitable for use in resource-poor settings.

Professor Fairlamb said that fexinidazole has the potential to become a safe and effective oral drug therapy for treating the severest form of visceral leishmaniasis.

"Visceral leishmaniasis is a neglected disease of poverty which causes huge problems across Africa, Asia and Latin America, killing tens of thousands of people every year," said Professor Fairlamb.

"The current treatments are far from ideal and we need to find better, cheaper and more easily delivered drugs to tackle the disease. Our research suggests that fexinidazole has strong potential to do that.

"Drugs for Neglected Diseases initiative have already established that fexinidazole is safe in early clinical trials for African sleeping sickness, so it is some way along the development path.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post